Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)

BACKGROUND: Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin‐23. It is approved for treatment of moderate–severe chronic plaque psoriasis. OBJECTIVES: We conducted a 52‐week retrospective study to assess the effectiveness and safety of tildrakizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Narcisi, Alessandra, Valenti, Mario, Gargiulo, Luigi, Ibba, Luciano, Amoruso, Fabrizio, Argenziano, Giuseppe, Bardazzi, Federico, Burlando, Martina, Carrera, Carlo Giovanni, Damiani, Giovanni, Dapavo, Paolo, Dini, Valentina, Franchi, Chiara, Girolomoni, Giampiero, Guarneri, Claudio, Loconsole, Francesco, Sampogna, Francesca, Travaglini, Massimo, Malagoli, Piergiorgio, Costanzo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092064/
https://www.ncbi.nlm.nih.gov/pubmed/36156312
http://dx.doi.org/10.1111/jdv.18594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092064/
https://www.ncbi.nlm.nih.gov/pubmed/36156312
http://dx.doi.org/10.1111/jdv.18594

Ejemplares similares